Evolution of hepatitis B and C serum markers: A still challenging issue

Liver International

Volumn 31, Issue 7, 2011, Pages 905-907

  Chemin, Isabelle ^a,b,c   Trépo, Christian ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN;

EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; NONHUMAN; SEROCONVERSION; VACCINATION; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

BIOLOGICAL MARKERS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; SEROLOGIC TESTS;

EID: 79960093058     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02479.x     Document Type: Editorial

References (20)

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 (Suppl. 1): 3-8.
2. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol 2008; 48: 335-52.
3. Shneider BL, Gonzalez-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD summary of a single topic conference. Hepatology 2006; 44: 1344-54.
4. Grob P, Jilg W, Bornhak H, et al. Serological pattern 'anti-HBc alone' report on a workshop. J Med Virol 2000; 62: 450-5.
5. Berger A, Presier W, Doerr HW. The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. J Clin Virol 2001; 20: 23-30.
6. Moore C, Barbara J, Hewitt PE. Anti-HBc in blood donors. Vox Sang 1998; 74: 209.
7. Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50: 693-6.
8. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C Hepatitis: a national heart, lung, and blood institute collaborative study. Hepatology 2001; 33: 455-63.
9. Simon N, Courouce AM, Lemarrec N, Trepo C, Ducamp S. A twelve-year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46: 504-11.
10. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
11. Pollicino T, Squadrito G, Cerenzia G, et al. Raimondo Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.
12. Ikeda K, Kobayashi M, Someya T, et al. Kumada H Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 6: 437-43.
13. Berger A, Doerr HW, Rabenau HF, Weber B. High frequency of HCV infection in individuals with isolated antibody to hepatitis B core antigen. Intervirology 2000; 43: 71-6.
14. Hofer M, Joller-Jemelka HI, et al. The Swiss HIV Cohort Study. Frequent chronic hepatitis B virus infection in HIV infected patients positive for antibody to hepatitis B core antigen only. Eur J Clin Micobiol Infect Dis 1998; 17: 6-13.
15. Castillo I, Rodríguez-Iñigo E, Bartolomé J, et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection. Gut 2005; 5: 682-5.
16. Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 1: 7-14.
17. Chamie G, Bonacini M, Bangsberg D, et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis 2007; 44: 577-83.
18. Toyoda H, Kumada T, Kiriyama S, et al. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. Clin Infect Dis 2005; 40: e49-54.
19. Lai CC, Tan CK, Huang YT, et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a medical center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
20. Tsai P-S, Chang C-J, Chen K-T, et al. Acquirement and disappearance of HBsAg and anti-HCV in an aged population: a follow-up study in an endemic township. Liver Int 2011; 31: 971-9.